期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Neoadjuvant camrelizumab(an anti-PD-1 antibody)plus chemotherapy or apatinib(a VEGFR-2 inhibitor)for initially unresectable stage II–III non-small-cell lung cancer:a multicentre,two-arm,phase 2 exploratory study 被引量:1
1
作者 Haoran Xia Han Zhang +26 位作者 Zheng Ruan Huibiao Zhang Liangdong Sun Hezhong Chen Yongxin Zhou Lele Zhang dongliang bian Xinsheng Zhu Jing Zhang Fenghuan Sun Huansha Yu Nan Song Xiaogang Liu Yuming Zhu Haiping Zhang Wenxin He Jian Chen Jie Yang Guohan Chen Shiliang Xie Dongfang Tang Xiaomiao Zhang Liang Duan Deping Zhao Qinchuan Li Peng Zhang Gening Jiang 《Signal Transduction and Targeted Therapy》 SCIE CSCD 2024年第7期3015-3023,共9页
This multicentre,two-arm,phase 2 study aimed to explore the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy or apatinib in patients with initially unresectable stage II–III non-small-cell lung cance... This multicentre,two-arm,phase 2 study aimed to explore the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy or apatinib in patients with initially unresectable stage II–III non-small-cell lung cancer(NSCLC).Eligible patients regardless of PD-L1 expression received neoadjuvant camrelizumab 200 mg and platinum-doublet chemotherapy every 3 weeks(arm A)or those with PD-L1-positive tumors received neoadjuvant camrelizumab and apatinib 250 mg once daily(arm B),for 2–4 cycles,followed by surgery.The primary endpoint was major pathological response(MPR)rate.Thirty patients in arm A and 21 in arm B were enrolled.Surgery rates were 50.0%(15/30)in arm A and 42.9%(9/21)in arm B,with all patients achieving R0 resections.Of these patients,the MPR and pathological complete response rates were both 20.0%(95%CI 4.3–48.1)in arm A and were 55.6%(95%CI 21.2–86.3)and 11.1%(95%CI 0.3–48.2)in arm B,respectively.The corresponding objective response rates were 33.3%(95%CI 11.8–61.6)and 55.6%(95%CI 21.2–86.3).With a median follow-up of 22.4 months(95%CI 19.0–26.0),the median event-free survival was not reached(NR;95%CI 13.6-NR)in arm A and 16.8 months(95%CI 8.6-NR)in arm B.Grade 3 or above treatment-related adverse events occurred in eight(26.7%)patients in arm A and three(14.3%)in arm B.Biomarker analysis showed baseline TYROBP expression was predictive of treatment response in arm B.Neoadjuvant camrelizumab plus chemotherapy or apatinib exhibits preliminary efficacy and manageable toxicity in patients with initially unresectable stage II–III NSCLC. 展开更多
关键词 Surgery CHEMOTHERAPY treatment
原文传递
Spatiotemporal evolution laws of sector-shaped dielectric-barrier-discharge plasma actuator
2
作者 Borui ZHENG Jianbo ZHANG +4 位作者 Shaojie QI Jianghua XU Yiche LI Yuanzhong JIN dongliang bian 《Plasma Science and Technology》 SCIE EI CAS 2024年第10期108-115,共8页
Dielectric barrier discharge(DBD)plasma actuators are widely used in active flow control due to their simple design and rapid responsiveness.However,they need more effectiveness and discharge extension.To overcome the... Dielectric barrier discharge(DBD)plasma actuators are widely used in active flow control due to their simple design and rapid responsiveness.However,they need more effectiveness and discharge extension.To overcome these limitations,a sector-shaped dielectric barrier discharge(SS-DBD)plasma actuator with an adjustable jet angle was developed to enhance flow control effectiveness.The flow field dynamics induced by the SS-DBD plasma actuator were quantitatively analyzed using particle image velocimetry(PIV).Experimental investigations showed that precise adjustments to the actuation voltage can modulate the maximum velocity of the induced jet.Furthermore,a quasi-linear relationship between the sector-shaped angles of the SS-DBD and the deflected jet angles was established,indicating that changes in the sector-shaped angles directly influence the direction of the deflected jet.This correlation enables precise control over jet angles,significantly enhancing flow control by adjusting the SS-DBD-PA's sector-shaped angle. 展开更多
关键词 plasma flow control plasma actuator particle image velocimetry
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部